ArticleRMD open2023

Correction: Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.